RT Journal Article
SR Electronic
T1 Effect of liraglutide on body weight and pain in patients with overweight and knee osteoarthritis: protocol for a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial
JF BMJ Open
JO BMJ Open
FD British Medical Journal Publishing Group
SP e024065
DO 10.1136/bmjopen-2018-024065
VO 9
IS 5
A1 Gudbergsen, Henrik
A1 Henriksen, Marius
A1 Wæhrens, Eva Ejlersen
A1 Overgaard, Anders
A1 Bliddal, Henning
A1 Christensen, Robin
A1 Boesen, Mikael Ploug
A1 Knop, Filip Krag
A1 Astrup, Arne
A1 Rasmussen, Marianne Uggen
A1 Bartholdy, Cecilie
A1 Daugaard, Cecilie
A1 Bartels, Else Marie
A1 Ellegaard, Karen
A1 Heitmann, Berit Lilienthal
A1 Kristensen, Lars Erik
YR 2019
UL http://bmjopen.bmj.com/content/9/5/e024065.abstract
AB Introduction With an increasing prevalence of citizens of older age and with overweight, the health issues related to knee osteoarthritis (OA) will intensify. Weight loss is considered a primary management strategy in patients with concomitant overweight and knee OA. However, there are no widely available and feasible methods to sustain weight loss in patients with overweight and knee OA. The present protocol describes a randomised controlled trial evaluating the efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide in a 3 mg/day dosing in patients with overweight and knee OA.Methods and analysis 150 volunteer adult patients with overweight or obesity and knee OA will participate in a randomised, double-blind, placebo-controlled, parallel-group and single-centre trial. The participants will partake in a run-in diet intervention phase (week −8 to 0) including a low calorie diet and dietetic counselling. At week 0, patients will be randomised to either liraglutide 3 mg/day or liraglutide placebo 3 mg/day for 52 weeks as an add-on to dietetic guidance on re-introducing regular foods and a focus on continued motivation to engage in a healthy lifestyle. The co-primary outcomes are changes in body weight and the Knee Injury and Osteoarthritis Outcome Score pain subscale from week 0 to week 52.Ethics and dissemination The trial has been approved by the regional ethics committee in the Capital Region of Denmark, the Danish Medicines Agency and the Danish Data Protection Agency. An external monitoring committee (The Good Clinical Practice Unit at Copenhagen University Hospitals) will oversee the trial. The results will be presented at international scientific meetings and through publications in peer-reviewed journals.Trial registration numbers 2015-005163-16, NCT02905864, U1111-1171-4970Based on protocol version V.6; 30 January 2017, 15:30 hours